Chromium Picolinate

About

What it is and where it shows up.

Chromium picolinate is a synthetically produced complex of trivalent chromium (Cr(III)) chelated with three molecules of picolinic acid, formulated to enhance the oral bioavailability of dietary chromium. It is added to food supplements and fortified foods and is primarily marketed for potential benefits in blood glucose regulation, insulin sensitivity, and weight management.

Safety summary

The regulatory and scientific consensus.

EFSA concluded that chromium picolinate use in foods and supplements is not of safety concern provided total supplemental chromium intake does not exceed 250 µg/day (the WHO upper guidance value), supported by a margin of safety of at least four orders of magnitude relative to the NOAEL. In vitro genotoxicity studies at high concentrations suggest possible DNA damage, but this finding has not been reproduced in standard in vivo assays. The FDA found the evidence linking chromium picolinate to reduced insulin resistance 'highly uncertain', and people with diabetes, kidney disease, or liver disease should consult a physician before use.

Regulatory landscape

What food-safety regulators have decided.

Jurisdiction	Status	Note
EFSA (European Food Safety Authority) (European Union)	Approved	Authorised as a novel food and as a source of chromium added for nutritional purposes to foods for particular nutritional uses (PARNUTS) and foods intended for the general population, including food supplements. Safety is conditional on total chromium from supplemental sources not exceeding 250 µg/day (0.25 mg/day), consistent with the WHO upper guidance value. Specifications must also ensure chromium(VI) impurity levels are kept as low as possible.source
FDA (Food and Drug Administration) (United States)	Approved	Regulated as a dietary supplement under the Dietary Supplement Health and Education Act (DSHEA, 1994). FDA issued a letter of enforcement discretion for one qualified health claim on chromium picolinate and reduced risk of insulin resistance, but concluded the relationship is 'highly uncertain'. No formal maximum daily intake level has been established at the federal level for dietary supplement use. Product-level misbranding and CGMP violations have been cited in some warning letters where therapeutic claims were made.source

Who should approach with care

Whose guidance would steer them away.

Kidney Disease — Chromium is primarily excreted renally; impaired kidney function can lead to chromium accumulation, increasing the risk of toxicity at supplemental doses.

Liver Disease — Liver disease may impair the metabolism and clearance of chromium complexes; supplemental use should be medically supervised.

Diabetes — Chromium picolinate may alter insulin sensitivity and blood glucose, potentially interacting with anti-diabetic medications and increasing hypoglycaemia risk, as noted in FDA and NIH ODS reviews.

Pregnancy — Animal studies examined pre- and postnatal exposure to chromium picolinate and raised neurological development questions; insufficient evidence supports the safety of supplemental doses beyond normal dietary chromium intake during pregnancy.

Children — EFSA has not established a paediatric-specific upper intake level for supplemental chromium, and safety data for chromium picolinate supplementation in children are lacking.

Research citations

The sources behind this verdict.

1other. Chromium — Health Professional Fact Sheet (NIH Office of Dietary Supplements). ods.od.nih.gov
2EFSA. Scientific Opinion on the safety of chromium picolinate as a source of chromium added for nutritional purposes to foodstuff for particular nutritional uses and to foods intended for the general population, 2010. efsa.europa.eu
3PubMed. Chronic toxicity and carcinogenicity studies of chromium picolinate monohydrate administered in feed to F344/N rats and B6C3F1 mice for 2 years, 2009. pubmed.ncbi.nlm.nih.gov
4FDA. Chromium picolinate intake and risk of type 2 diabetes: an evidence-based review by the United States Food and Drug Administration, 2006. pubmed.ncbi.nlm.nih.gov
5IARC. Chromium, Nickel and Welding — IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Volume 49, 1990. publications.iarc.who.int

Independently researched5 citations